Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

 

International Congress of Parkinson’s Disease and Movement Disorders ®

Congress

Plenary Session 4206

Disease-Modifying Trials for Parkinson’s Disease: Past, Present and Future

Wednesday, October 8, 2025
10:00 - 11:30 | Ballroom

In this session, the faculty will discuss recent and ongoing disease modifying trials in Parkinson's disease. Challenges in clinical trial design and the way forward will be discussed.

Chairs:

Susan Fox, Canada
Nobutaka Hattori, Japan

Presenters:

Recent and Ongoing Trials
Tatyana Simuni, USA

Challenges in Patient Selection
Camille Carroll, United Kingdom

Challenges in Trial Design
Olivier Rascol, France

CSPC Liaisons:

Huw Morris, United Kingdom

Learning Objectives

At the conclusion of this session, participants should be better able to:

  1. Discuss recent and ongoing or in development trials for disease modification in Parkinson's disease
  2. Discuss challenges in patient selection including biomarkers and recruitment of prodromal subjects
  3. Discuss the importance of improving outcome measures including multi-arm multi-stage trial design, remote monitoring and digital technologies

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Health Professional (non-physician)
Industry
Researcher / Basic Science

Education Level

Advanced / Expert
Beginner / Foundational
Intermediate / Experienced

Focus

Clinical